Louis Picker, HIVR4P 2021: CMV-vector vaccines for HIV Prevention
It was a pleasure to speak with Louis Picker (VGTI-Vaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, OR, USA) to discuss his work in CMV-vector vaccines for HIV prevention.
The abstract entitled: ‘CMV-vectored vaccines for HIV prevention’ (SY09.03) was presented at the HIVR4P Virtual Conference 2021, 04 February 2021.
- Could you give us an overview of the current status of vaccine development for HIV and its unmet needs? (0:14)
- What is the rationale for using cytomegalovirus (CMV) as a vaccine vector for HIV? (0:29)
- What are the challenges in the development and use of CMV-vectored vaccines? (4:05)
- What preclinical and clinical evidence supports the use of CMV-vectored vaccines? (6:28)
- What safety concerns are associated with this approach? (8:25)
Disclosures: Louis Picker is the Founder of, and Consultant for, Vir Biotechnology, Inc., which is developing CMV-based vaccine vector for clinical use.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of HIVR4P Virtual 2021.
Share this Video
Related Videos In Viral Infections
DANFLU-1: post-hoc analysis of high-dose quadrivalent influenza vaccines: Niklas Dyrby Johansen, ECCMID 2023
DANFLU-1 was an open-label, active-controlled, individually randomized trial conducted in Denmark during the 2021/2022 northern hemisphere influenza season. Dr Niklas Dyrby Johansen (University of Copenhagen Copenhagen, Denmark) discusses the post-hoc analysis from DANFLU-1 which investigated the effects of high-dose quadrivalent influenza vaccine (QIV-HD) vs standard-dose quadrivalent influenza vaccine (QIV-SD). The abstract ‘Relative effectiveness of high-dose […]
Michael Ison, IDWeek 2022: Respiratory syncytial virus (RSV) – Health burden and current vaccine candidates
Respiratory syncytial virus (RSV) present a significant disease burden in children and older adults. Currently, there are no approved vaccines against RSV. In this touchINFECTIOUS DISEASES interview, we met with Prof. Michael Ison (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss the health burden of RSV infection in older adults, and current […]
Michael Ison, IDWeek 2022: Respiratory syncytial virus (RSV) prefusion F protein candidate vaccine RSVPreF3 OA – Ongoing phase 3 study results
Respiratory syncytial virus (RSV) presents a significant disease burden in older adults, with no approved vaccines to protect against RSV. In this touchINFECTIOUS DISEASES interview, we met with Prof. Michael Ison (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss the findings from an ongoing phase 3 study investigating vaccine efficacy of the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!